Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Gordon

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1995
HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteersB Wizel, R Houghten, P Church, et al.
Lancet (London, England)|May 7, 1991
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccineL S Rickman, D M Gordon, R Wistar, et al.
The Journal of Infectious Diseases|June 1, 1995
Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccineD M Gordon, T W McGovern, U Krzych, et al.
European Journal of Immunology|November 1, 1995
The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigenH A Stephens, A E Brown, D Chandanayingyong, et al.
Vaccine|January 1, 1992
Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cellsD A Herrington, G A Losonsky, G Smith, et al.
Parasitology|January 1, 1995
Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy studyW R Ballou, J Blood, T Chongsuphajaissidhi, et al.
Infection and Immunity|May 1, 1992
Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin AL F Fries, D M Gordon, I Schneider, et al.
The American Journal of Tropical Medicine and Hygiene|May 1, 1997
Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast AsiaF Nosten, C Luxemburger, D E Kyle, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1992
Characterization of Plasmodium falciparum sporozoite surface protein 2W O Rogers, A Malik, S Mellouk, et al.
The American Journal of Tropical Medicine and Hygiene|July 11, 1991
Significance of circumsporozoite-specific antibody in the natural transmission of Plasmodium falciparum, Plasmodium vivax, and Plasmodium malariae in an aboriginal (Orang Asli) population of central peninsula MalaysiaD M Gordon, D R Davis, M Lee, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1995
HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteersB Wizel, R Houghten, P Church, et al.
Lancet (London, England)|May 7, 1991
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccineL S Rickman, D M Gordon, R Wistar, et al.
The Journal of Infectious Diseases|June 1, 1995
Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccineD M Gordon, T W McGovern, U Krzych, et al.
European Journal of Immunology|November 1, 1995
The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigenH A Stephens, A E Brown, D Chandanayingyong, et al.
Vaccine|January 1, 1992
Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cellsD A Herrington, G A Losonsky, G Smith, et al.
Parasitology|January 1, 1995
Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy studyW R Ballou, J Blood, T Chongsuphajaissidhi, et al.
Infection and Immunity|May 1, 1992
Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin AL F Fries, D M Gordon, I Schneider, et al.
The American Journal of Tropical Medicine and Hygiene|May 1, 1997
Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast AsiaF Nosten, C Luxemburger, D E Kyle, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1992
Characterization of Plasmodium falciparum sporozoite surface protein 2W O Rogers, A Malik, S Mellouk, et al.
The American Journal of Tropical Medicine and Hygiene|July 11, 1991
Significance of circumsporozoite-specific antibody in the natural transmission of Plasmodium falciparum, Plasmodium vivax, and Plasmodium malariae in an aboriginal (Orang Asli) population of central peninsula MalaysiaD M Gordon, D R Davis, M Lee, et al.
Pageof 11